These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca2+ cascades. Parma J; Van Sande J; Swillens S; Tonacchera M; Dumont J; Vassart G Mol Endocrinol; 1995 Jun; 9(6):725-33. PubMed ID: 8592518 [TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. Paschke R; Tonacchera M; Van Sande J; Parma J; Vassart G J Clin Endocrinol Metab; 1994 Dec; 79(6):1785-9. PubMed ID: 7989485 [TBL] [Abstract][Full Text] [Related]
5. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. Russo D; Arturi F; Suarez HG; Schlumberger M; Du Villard JA; Crocetti U; Filetti S J Clin Endocrinol Metab; 1996 Apr; 81(4):1548-51. PubMed ID: 8636365 [TBL] [Abstract][Full Text] [Related]
6. Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas. Castro I; Lima L; Seoane R; Lado-Abeal J Thyroid; 2009 Jun; 19(6):645-9. PubMed ID: 19499991 [TBL] [Abstract][Full Text] [Related]
7. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. Parma J; Duprez L; Van Sande J; Hermans J; Rocmans P; Van Vliet G; Costagliola S; Rodien P; Dumont JE; Vassart G J Clin Endocrinol Metab; 1997 Aug; 82(8):2695-701. PubMed ID: 9253356 [TBL] [Abstract][Full Text] [Related]
8. Somatic mutations in the VI transmembrane segment of the thyrotropin receptor constitutively activate cAMP signalling in thyroid hyperfunctioning adenomas. Porcellini A; Ciullo I; Pannain S; Fenzi G; Avvedimento E Oncogene; 1995 Sep; 11(6):1089-93. PubMed ID: 7566968 [TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Parma J; Duprez L; Van Sande J; Cochaux P; Gervy C; Mockel J; Dumont J; Vassart G Nature; 1993 Oct; 365(6447):649-51. PubMed ID: 8413627 [TBL] [Abstract][Full Text] [Related]
10. [Non-autoimmune hyperthyroidism and hyperfunctioning thyroid adenomas caused by activating mutation of the thyrotropin receptor]. Kosugi S Nihon Rinsho; 2002 Feb; 60(2):291-6. PubMed ID: 11857916 [TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. Derwahl M; Hamacher C; Russo D; Broecker M; Manole D; Schatz H; Kopp P; Filetti S J Clin Endocrinol Metab; 1996 May; 81(5):1898-904. PubMed ID: 8626855 [TBL] [Abstract][Full Text] [Related]
14. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. Takeshita A; Nagayama Y; Yokoyama N; Ishikawa N; Ito K; Yamashita T; Obara T; Murakami Y; Kuma K; Takamatsu J J Clin Endocrinol Metab; 1995 Sep; 80(9):2607-11. PubMed ID: 7673402 [TBL] [Abstract][Full Text] [Related]
15. Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. Porcellini A; Ciullo I; Laviola L; Amabile G; Fenzi G; Avvedimento VE J Clin Endocrinol Metab; 1994 Aug; 79(2):657-61. PubMed ID: 8045989 [TBL] [Abstract][Full Text] [Related]
16. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Paschke R Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():129-32. PubMed ID: 8981020 [TBL] [Abstract][Full Text] [Related]
17. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor. Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132 [TBL] [Abstract][Full Text] [Related]
18. Hyperfunctioning thyroid adenoma and activating mutations in the TSH receptor gene. Polak M Arch Med Res; 1999; 30(6):510-3. PubMed ID: 10714365 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of mutations in TSHR, GNAS, PRKAR1A and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. Palos-Paz F; Perez-Guerra O; Cameselle-Teijeiro J; Rueda-Chimeno C; Barreiro-Morandeira F; Lado-Abeal J; ; Araujo Vilar D; Argueso R; Barca O; Botana M; Cabezas-Agrícola JM; Catalina P; Dominguez Gerpe L; Fernandez T; Mato A; Nuño A; Penin M; Victoria B Eur J Endocrinol; 2008 Nov; 159(5):623-31. PubMed ID: 18694911 [TBL] [Abstract][Full Text] [Related]
20. Two novel mutations in the sixth transmembrane segment of the thyrotropin receptor gene causing hyperfunctioning thyroid nodules. Gozu H; Avsar M; Bircan R; Claus M; Sahin S; Sezgin O; Deyneli O; Paschke R; Cirakoglu B; Akalin S Thyroid; 2005 Apr; 15(4):389-97. PubMed ID: 15876166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]